Protection associated with a TB vaccine is linked to increased frequency of Ag85A-specific CD4+ T cells but no increase in avidity for Ag85A by Metcalfe, Hannah J. et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protection associated with a TB vaccine is linked to increased
frequency of Ag85A-specific CD4+ T cells but no increase in
avidity for Ag85A
Citation for published version:
Metcalfe, HJ, Steinbach, S, Jones, GJ, Connelley, T, Morrison, WI, Vordermeier, M & Villarreal-ramos, B
2016, 'Protection associated with a TB vaccine is linked to increased frequency of Ag85A-specific CD4+ T
cells but no increase in avidity for Ag85A', Vaccine, vol. 34, no. 38, pp. 4520-4525.
https://doi.org/10.1016/j.vaccine.2016.07.055
Digital Object Identifier (DOI):
10.1016/j.vaccine.2016.07.055
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Vaccine
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 11. May. 2020
Vaccine xxx (2016) xxx–xxxContents lists available at ScienceDirect
Vaccine
journal homepage: www.elsevier .com/locate /vacc ineProtection associated with a TB vaccine is linked to increased frequency
of Ag85A-specific CD4+ T cells but no increase in avidity for Ag85Ahttp://dx.doi.org/10.1016/j.vaccine.2016.07.055
0264-410X/ 2016 Published by Elsevier Ltd.
⇑ Corresponding author at: Animal and Plant Health Agency (APHA), TB
Immunology and Vaccinology Team, New Haw, Addlestone, Surrey KT15 3NB, UK.
E-mail address: Bernardo.Villarreal-Ramos@apha.gsi.gov.uk (B. Villarreal-
Ramos).
1 These authors are joint first authors.
2 These authors are joint senior authors.
Please cite this article in press as: Metcalfe HJ et al. Protection associated with a TB vaccine is linked to increased frequency of Ag85A-specific CD4+
but no increase in avidity for Ag85A. Vaccine (2016), http://dx.doi.org/10.1016/j.vaccine.2016.07.055Hannah J. Metcalfe a,b,1, Sabine Steinbach a,1, Gareth J. Jones a, Tim Connelley b, W. Ivan Morrison b,
Martin Vordermeier a,2, Bernardo Villarreal-Ramos a,⇑,2
a TB Immunology and Vaccinology Team, Department of Bacteriology, Animal and Plant Health Agency, Weybridge, Surrey KT15 3NB, UK
b Immunity Division, The Roslin Institute, Royal (Dick) School of Veterinary Studies, University of Edinburgh, Easter Bush, Midlothian EH25 9RG, UKa r t i c l e i n f o
Article history:
Received 10 May 2016
Received in revised form 26 July 2016
Accepted 28 July 2016
Available online xxxx
Keywords:
Bovine tuberculosis
Vaccination
Immunological protectiona b s t r a c t
There is a need to improve the efficacy of Bacille Calmette-Guérin (BCG) vaccination against tuberculosis
in humans and cattle. Previously, we found boosting BCG-primed cows with recombinant human type 5
adenovirus expressing antigen 85A (Ad5-85A) increased protection againstMycobacterium bovis infection
compared to BCG vaccination alone. The aim of this study was to decipher aspects of the immune
response associated with this enhanced protection. We compared BCG-primed Ad5-85A-boosted cattle
with BCG-vaccinated cattle. Polyclonal CD4+ T cell libraries were generated from pre-boost and post-
boost peripheral blood mononuclear cells – using a method adapted from Geiger et al. (2009) – and
screened for antigen 85A (Ag85A) specificity. Ag85A-specific CD4+ T cell lines were analysed for their
avidity for Ag85A and their Ag85A epitope specificity was defined. Boosting BCG with Ad5-85A increased
the frequencies of post-boost Ag85A-specific CD4+ T cells which correlated with protection (reduced
pathology). Boosting Ag85A-specific CD4+ T cell responses did not increase their avidity. The epitope
specificity was variable between animals and we found no clear evidence for a post-boost epitope spread-
ing. In conclusion, the protection associated with boosting BCG with Ad5-85A is linked with increased
frequencies of Ag85A-specific CD4+ T cells without increasing avidity or widening of the Ag85A-
specific CD4+ T cell repertoire.
 2016 Published by Elsevier Ltd.1. Introduction
Mycobacterium bovis, the main cause of bovine tuberculosis
(bTB), is a world-wide problem and is endemic in the south west
of England and parts of Wales [1–3]. As well as having a significant
economic impact, infection of cattle with M. bovis presents a risk
for human health. The incidence of bTB may be exacerbated by
wild-life reservoirs which are not easy to monitor accurately and
therefore there is a need to implement supplementary measures
to the current control methods [1,2,4,5]. Vaccination of cattle
would be a logistically convenient measure for controlling bTB [6].
To date, the live attenuated M. bovis Bacille Calmette-Guérin
(BCG) is the only available vaccine against TB but it has variableefficacy in both humans and cattle (reviewed elsewhere [7–9]).
Nevertheless, strategies which boost BCG protection are being
explored because of the efficacy of BCG against non-pulmonary
infections [10]. One such strategy is boosting BCG with viral vec-
tors expressing mycobacterial proteins such as antigen 85A
(Ag85A).
Ag85A is one of a family of three secreted and membrane
retained enzyme isoforms, highly conserved across mycobacteria
and involved in the synthesis of important constituents for the cell
wall [11–13]. These proteins are classed as virulence factors
because they are thought to promote bacterial survival in macro-
phages along with adhesion/invasion and dissemination in host
cells [13]. Ag85A is also an immunogenic Ag that is recognised
by T cells and it is considered a potential candidate for boosting
cellular immunity primed by BCG [14,15].
Protection against mycobacteria has been shown to be medi-
ated mainly by T cells [16]. CD4+ T cells are thought to be particu-
larly important; depletion of CD4+ T cells in small animal models
has been shown to reduce protection against infection with
mycobacteria to a greater extent than depletion of other T cell
types [17].T cells
2 H.J. Metcalfe et al. / Vaccine xxx (2016) xxx–xxxPreviously, we showed that boosting BCG with viral vectors
such as human type 5 adenovirus (Ad5) or Modified Vaccinia
Ankara virus expressing Ag85A reduced the number of animals
presenting TB lesions/granulomas in cattle infected with M. bovis
[18,19]. However, there is a need to understand the immune mech-
anisms associated with the observed protection to devise means of
improving future vaccine development. We hypothesised that
enhanced immunity is associated with the magnitude, avidity
and specificity of the CD4+ T cell response to Ag85A. To test this
hypothesis, CD4+ T cell libraries were generated from BCG primed
and Ad5-85A boosted animals using a method adapted from Geiger
et al. [20] and compared to CD4+ T cell libraries generated from
BCG control cattle. Ag85A-specific CD4+ T cell lines were selected
for avidity studies and analysis of T cell receptor epitope
specificity.
2. Materials and methods
2.1. Vaccine experiment
The biological materials used in this study were derived from a
vaccine experiment described previously by Dean et al. [19].
Animal work was carried out according to the UK Animal (Scien-
tific Procedures) Act 1986. The study protocol was approved by
the APHA Animal Use Ethics Committee (UK Home Office PCD
number 70/6905). Briefly, all animals were vaccinated with
1  106 colony forming units (CFU) M. bovis BCG Danish 1331 sub-
cutaneously at week (wk) 0; Ad5-85A boosted cows were inocu-
lated at wk 8 with 1  109 infectious units of Ad5-85A by
intradermal injection on the shoulder; all animals were challenged
endobronchially with 2  103 CFU M. bovis AF2122/97 strain at wk
12. Total pathology score was determined at post-mortem exami-
nation at wk 26 [19]. The present study utilised cryopreserved
PBMC collected from nine BCG-primed Ad5-85A-boosted cows
and six BCG-vaccinated control cows.
2.2. CD4+/CD14+ cell sorting and culture
CD4+ and CD14+ T-cells were isolated as previously described
[21]. Briefly, CD4+ T cells from PBMC were labelled with mAb
CC8 to bovine CD4 (Bio-Rad AbD Serotec) and isolated using para-
magnetic beads conjugated to rat anti-mouse IgG2 (Miltenyi) as
described by the manufacturer’s instructions. CD14 cells from
PBMC were isolated using paramagnetic beads conjugated to anti-
bodies against human CD14 (Miltenyi) as described by the manu-
facturer’s instructions. CD4+ and CD14+ cell purities were assessed
by flow cytometry and found to be >95%. Cells were cultured in
RPMI 1640 containing 2 mM GlutaMax, 25 mM HEPES, 0.1 mM
NEAA, 5  105 M b-mercaptoethanol, 100 U/ml penicillin and
100 lg/ml streptomycin (all from Gibco Life Technologies, UK)
and 10% FCS (Sigma-Aldrich, UK).
2.3. CD4+ T cell libraries
Polyclonal CD4+ T cell libraries were generated from pre-boost
(wk 8) and post-boost (wk 11) PBMC using a method adapted from
Geiger et al. [20]. Autologous feeder cells were prepared by treat-
ing wk 0 PBMC with 50 lg/ml mitomycin C (Sigma-Aldrich) in
PBS, at a density of 107 PBMC/ml, for 30 min at 37 C. Polyclonal
libraries were generated in 96-well flat-bottom plates using
6  104 autologous feeder cells/well and 4  103–1  104 CD4+ T
cells/well from BCG-vaccinated control samples or 1  103–
5  103 CD4+ T cells/well from post-Ad5-85A boost samples.
CD4+ T cells were stimulated with 1 lg/ml lectin from Phaseolus
vulgaris leucoagglutinin (PHA) (Sigma-Aldrich) in the presence ofPlease cite this article in press as: Metcalfe HJ et al. Protection associated with a
but no increase in avidity for Ag85A. Vaccine (2016), http://dx.doi.org/10.101610 U/ml recombinant human interleukin 2 (IL-2) (Gentaur, Bel-
gium). Libraries were fed with 10 U/ml IL-2 on day 5, expanded
and fed where necessary between days 6–8, and half the medium
was replaced with cytokine-free medium on day 9. 1  105–
2  105 CD4+ T cells per library well were screened for Ag85A-
specificity on day 11 using antigen presenting cells (APC) adhered
to flat-bottom 96-well plates (2 h adhesion of 1  105 PBMC/well,
washed 3 with HBSS (Gibco)) either unpulsed (negative control)
or pulsed with 5 lg/ml Ag85A (Lionex, Germany) for 3 days.2.4. Antigen-specific proliferation assay
Proliferation was determined on day 4 after radiolabelling
cells for 16 h with [Methyl-3H]-thymidine (3H-TdR) (1 lCi/well,
24.7 Ci/mmol, Perkin Elmer, USA). Cells were harvested onto
96-well glass filter plates (UniFilter-96, GF/C – PerkinElmer, USA)
using a Harvester 96 Mach III (TomTec Inc., USA) and analysed
for radioactivity using a MicroBeta2 2450 (Perkin Elmer) plate
counter.
Positive Ag85A-responses in the 96-well CD4+ T cell libraries
had to pass the following criteria:
(1) Ag85A counts per min (cpm)/negative control cpmP 2
And:
(2) Ag85A cpm – negative control cpmP the mean of all the
negative controls in the 96-well library plate.
Ag85A-specific CD4+ T cell line frequencies were calculated
based on >37% negative wells according to the Poisson distribution
and expressed per million CD4+ T cells [22].2.5. Ag85A-specific CD4+ T cell line maintenance
Ag85A-specific CD4+ T cells were selected from 1  105–2  105
CD4+ T cells using 5 lg/ml (initial screen) or 10 lg/ml (after
selection) Ag85A and 5  103 CD14+ APC per well of 96-well
U-bottom plates; this was carried out in parallel to the prolifera-
tion assays for 11 days. Cells were fed with 10 U/ml IL-2 on day
4/7; replacing half the medium with cytokine-free medium on
day 9. Ag85A-specific CD4+ T cell lines were expanded after each
selection using PHA/IL2 (plus CD14+ APC) for 9 days and cryopre-
served. Ag85A-specific CD4+ T cell line avidity was determined
after the first cryopreservation (3rd passage: PHA-Ag85A-PHA)
and epitope specificity was determined after the second
cryopreservation (5th passage: PHA-Ag85A-PHA-Ag85A-PHA).2.6. Ag85A avidity and peptide assays
The avidity of each Ag85A-specific CD4+ T cell line (1  105
cells/well in a 96-well U-bottom plate) was assessed using
5  103 CD14+ APC/well in an Ag85A-dose dependent 3H-TdR pro-
liferation assay. Each of the dose-dependent proliferation curves
was normalised by dividing by the highest cpm value (=1). Half
maximal effective concentration (EC50) values were calculated
from the sigmoidal curves using a nonlinear regression curve as
illustrated in supplementary Fig. 1. The epitope specificity of indi-
vidual Ag85A-specific CD4+ T cell lines was assessed using six pools
of eleven synthetic peptides covering Ag85A: fifteen amino acid
(aa) long and overlapping by ten residues (Mimotopes Pty Ltd.,
Australia). Individual peptides were used at a concentration of
5 lg/ml (for concentration of peptides in moles, please see supple-
mentary Table 1) with CD14+ APC in a 3H-TdR proliferation assay
(same cell concentrations as above). Each stimulation index (S.I.)
was calculated by dividing cpm from peptide pool treated cells
by the cpm of the negative control medium treated cells (S.I.TB vaccine is linked to increased frequency of Ag85A-specific CD4+ T cells
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Aldrich) was used as a positive proliferation control.
2.7. Statistics
All data analyses were performed using GraphPad Prism version
5.04 (GraphPad Software, La Jolla, CA, USA). Ag85A-specific CD4+ T
cell frequency data did not pass normality testing and was sub-
jected to the Wilcoxon matched-pairs signed rank test. Total
pathology score data did not pass normality testing therefore the
correlation between CD4+ T-cell frequency and pathology score
was determined using a nonparametric Spearman correlation
coefficient.
3. Results
3.1. Boosting BCG with Ad5-85A increases the frequency of Ag85A-
specific CD4+ T cells which correlate with protection against M. bovis
pathology
To evaluate the effect of boosting BCG with Ad5-85A on the fre-
quency of Ag85A-specific CD4+ T cells, CD4+ T cell libraries were
generated from pre-boost (wk 8) and post-boost (wk 11) PBMC
samples and compared to responses from animals vaccinated with
BCG alone. Wk 11 was selected as peripheral blood responses at
this time point had returned to background levels after the boost-
ing response increasing the chances of detecting memory
responses [19]; wk 11 was also the last sampling point after vacci-
nation prior to challenge. The frequencies of Ag85A-specific CD4+ T
cells in the Ad5-85A-boosted wk 11 (post-boost) libraries were
found to be significantly higher than the frequencies of Ag85A-
specific CD4+ T cells in the wk8 (pre-boost) libraries (Fig. 1A) – this
trend was not found in the BCG-vaccinated control animals. This
indicates that boosting BCG-vaccinated cattle with Ad5-85A
increased the frequencies of Ag85A-specific CD4+ T cells.
To determine whether increased Ag85A-specific CD4+ T cell fre-
quencies correlate with protection against M. bovis, wk 11 and wk
8 Ag85A-specific CD4+ T cell frequencies were plotted against the
total pathology scores that describe the extent and spread of tuber-
culous lesions within infected cattle (Fig. 1B). A significant negative
correlation was found between the frequencies of post-boost (wk
11) Ag85A-specific CD4+ T cells from Ad5-85A boosted animalsA. Ag85A Library screen
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cell libraries were generated from wk 8 and wk 11 PBMC samples collected from 9 BCG-p
screened for Ag85A-specific CD4+ T cells using the 3H-TdR proliferation assay as descri
(lines = median) and compared using the Wilcoxon matched-pairs signed rank test (ns =
cell frequencies (Y-axis) from the BCG-primed Ad5-85A-boosted cattle were plotted agai
Correlation Coefficient (data shown in the box). BCG-vaccinated control: wk 8 = up-side-
= circles; post-boost (wk 11) = squares.
Please cite this article in press as: Metcalfe HJ et al. Protection associated with a
but no increase in avidity for Ag85A. Vaccine (2016), http://dx.doi.org/10.1016and their respective pathology score (n = 9: r = 0.6331,
P = 0.0317) which was not observed when using frequency
data from pre-boost (wk 8) Ag85A-specific CD4+ T cells (n = 9:
r = 0.1743, P = 0.4696). This suggests the increase in Ag85A-
specific CD4+ T cell frequencies, observed 3 wk after boosting with
Ad5-85A, is associated with enhanced protection.
3.2. Assessment of T cell avidity pre- and post-boost
To further evaluate the functionality of Ag85A-specific CD4+ T
cell lines, an Ag85A-dose dependent proliferation assay was car-
ried out and EC50 values were calculated from the sigmoidal curves
using a nonlinear regression curve (supplementary Fig. 1). Fig. 2
illustrates comparisons of Ag85A-specific CD4+ T cell EC50 values
pre-boost and post-boost. We were able to make comparisons
between the EC50 values for 2 BCG animals (Fig. 2A) and for 3
BCG primed Ad5-85A boosted animals (Fig. 2B). Fig. 2C illustrates
Ag85A-specific CD4+ T cell EC50 values for all wk 8 Ag85A-
specific CD4+ T cell lines at pre-boost (all BCG and to be-boosted
animals – n = 9) and all Ad5-85A-boosted animals at wk 11
(post-boost, n = 5). Taken together, these data suggest that boost-
ing does not increase T cell avidity.
3.3. Boosting BCG with Ad5-85A leads to minimal epitope spreading
To map the regions of Ag85A recognised after BCG priming and
compare to the repertoire recognised post-Ad5-85A boost, the epi-
tope specificities of the Ag85A-specific CD4+ T cell lines were anal-
ysed using six pools of eleven peptides each (Fig. 3). There is
marked variation in epitope specificities between individual ani-
mals where: only #6642 reacted to pool one; #6509/#6639
reacted to pool two; after boosting all three animals reacted to pool
three which may contain the most dominant epitope; only #6509
reacted to pool four; and only #6642 reacted to pool six. Ag85A-
specific CD4+ T cell lines from these animals exhibited varying
levels of reactivity to the Ag85A protein (Fig. 3G) but they all had
the capacity to react to the PWM control (Fig. 3H). Only one out
of the three animals tested (#6509) exhibited a noticeable spread
in epitope specificity. This was indicated by positive reactions to
pool three from five cell lines derived from this animal out of the
eight post-boost Ag85A-specific CD4+ T cell lines; in comparison
to no positive reactions in the six pre-boost cell lines derived fromB. Ad5-85A-boosted cattle
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Fig. 2. Comparison of Ag85A-specific CD4+ T cell EC50 values from BCG vaccinated cows and BCG-primed Ad5-85A-boosted cows. Ag85A-specific CD4+ T cell lines were
evaluated in the Ag85A-dose dependent 3H-TdR proliferation assay and EC50 values were calculated from the sigmoidal curve using a nonlinear regression (Supplementary
Fig. 1). Figures A and B illustrate EC50 values (wk 8 vs wk 11) from 2 BCG-vaccinated control cows and 3 BCG-primed Ad5-85A-boosted cows, respectively. Figure C illustrates
all the Ag85A-specific CD4+ T cell EC50 values acquired from wk 8 (pre-boost) Ag85A-specific CD4+ T cell lines (from n = 9 animals) and Ad5-85A-boosted wk 11 (post-boost)
Ag85A-specific CD4+ T cell lines (from n = 5 animals). BCG-vaccinated control: wk 8 = up-side-down triangles; wk 11 = triangles. BCG-primed Ad5-85A-boosted: pre-boost
(wk 8) = circles; post-boost (wk 11) = squares. Horizontal lines represent the median. Statistical comparison in C was carried out using the Mann-Whitney test (ns = no
significance: P = 0.3313).
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Fig. 3. Pre- and Post-boost epitope specificities within Ag85A-specific CD4+ T cell lines from three BCG-primed and Ad5-85A-boosted cows. Ag85A-specific CD4+ T lines were
challenged with six pools of eleven overlapping Ag85A peptides in a 3H-TdR proliferation assay. Stimulation indexes (S.I.) for each of 3 Ad5-85A-boosted animals (X-axis)
were plotted in aligned dot-plots where open symbols represent pre-boost lines and closed symbols or crosses represent post-boost lines (left vs right, respectively, for each
animal). The horizontal dotted black line represents the S.I. threshold (=2).
4 H.J. Metcalfe et al. / Vaccine xxx (2016) xxx–xxxthe same animal (Fig. 3C). No such widening of the epitope reper-
toire was observed when the peptide pool reactions were com-
pared pre- and post-boost in the other two animals. These data
indicate that boosting BCG-vaccinated cattle with Ad5-85A induces
minimal epitope spreading.4. Discussion
In this study, we sought to determine whether increased pro-
tection against M. bovis infection, induced by boosting BCG with
Ad5-85A in cattle, was associated with changes in the: (i) fre-
quency of CD4+ T cells recognising Ag85A; (ii) avidity for Ag85A;
or (iii) changes in Ag85A epitope specificity. To this end, CD4+ T cell
libraries were generated – from animals used in previously pub-
lished vaccine efficacy experiments [19] – employing a method
adapted from Geiger et al. [20]. Analysis of these libraries, showed
that BCG vaccinated cattle boosted with Ad5-85A had increasedPlease cite this article in press as: Metcalfe HJ et al. Protection associated with a
but no increase in avidity for Ag85A. Vaccine (2016), http://dx.doi.org/10.1016frequencies of Ag85A-specific CD4+ T cells and this correlated with
enhanced protection againstM. bovis-induced pathology. However,
boosting with Ad5-85A did not enhance the avidity of the Ag85A-
specific CD4+ T cell lines nor significantly alter their epitope speci-
ficity. Samples used to generate the post-boost libraries were from
wk 11 – two weeks after the peak of the response following the
boost [19] – when IFNc whole blood responses had returned to
background levels. This increased the probability of detecting
memory responses rather than effector responses.
It has been shown that antigen (Ag) persistence – as well as
dose – can lead to CD4+ T cell exhaustion (or terminal differentia-
tion) [23–26]. However, as Lindenstrom et al. indicated, none of
these studies examined differences in avidity or cytotoxic potential
[25]. Results from the current study indicate that boosting BCG
vaccinated cattle with Ad5-85A did not increase avidity; rather
there may be a tendency to low avidity in two out of three post-
boost libraries compared to the opposite trend in BCG-vaccinated
control animals. A low Ag85A-specific avidity might be advanta-TB vaccine is linked to increased frequency of Ag85A-specific CD4+ T cells
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H.J. Metcalfe et al. / Vaccine xxx (2016) xxx–xxx 5geous during M. bovis infection because these cells may have
enhanced functional persistence during recall, as demonstrated
by Patke and Farber for influenza-specific CD4+ T cells [27]. Indeed,
Caserta et al. found, in situations of Ag persistence (e.g. tumour-
associated Ag), memory CD4+ T cells with low functional avidity
are more effective immune cells than those with high functional
avidity [28]. This may be due to: a delay in the expression of inhi-
bitory receptors (e.g. TIM3) which have been linked with T cell
exhaustion during bacterial recrudescence in chronic TB [29]; or
a reduced risk of T cell receptor down-regulation which has been
found to have a negative impact on the function (e.g. cytokine pro-
duction, recall proliferation and mycobacterial inhibition) of T cells
with high reactivity for ESAT6 in mice [30].
It is interesting to note one Ad5-85A boosted animal (#6639)
with the lowest post-boost EC50 values (high avidity) had the high-
est total pathology score in the Ad5-85A boosted group. However,
the frequencies of both pre- and post-boost Ag85A-specific CD4+ T
cells in this animal (#6639) were at the lower end of the spectrum
found in boosted cattle. This may suggest there was less efficient
BCG priming in this animal which may have restricted the
Ad5-85A boosting.
In this study, we foundminimal evidence of epitope spreading –
between the peptide pools – after boosting. In contrast, we found
marked variations in epitope specificities between animals, as seen
in the differences in Ag-specific reactivity to five out of the six
Ag85A peptide pools. This is likely to be a consequence of variation
in the Major Histocompatibility Complex (MHC) II alleles that pre-
sent antigen to CD4+ T cells. Indeed, molecular typing of animals
used in this experiment for one of the MHCII loci, DRB3 [31],
revealed diverse combinations of DRB3 alleles (data not shown)
which will lead to differences in the epitopes presented by differ-
ent animals. Diversity in MHC expression has been linked to vari-
ations in disease susceptibility [31] and it may have played a role
in the outcome of this experiment, i.e. some animals in the boosted
group were better protected than others.
Previous studies have reported different immunodominant
CD4+ and CD8+ T cell epitopes in the highly conserved Ag85 com-
plex (summarised by Huygen [32]). Interestingly, one of the three
Ad5-85A boosted animals in the present study had Ag85A-specific
CD4+ T cell responses to pool one (aa 1-55) (Fig. 3A) which includes
a region reported as a signal peptide (aa 1-33 [33]); we are not
aware of other studies that have reported epitopes in this region.
We also found the number of Ag85A-specific CD4+ T cell responses
to pool five (aa 221-285) was negligible (Fig. 3E) which is intrigu-
ing because at least one epitope with strong homology to this
region has been frequently reported in mice, guinea-pigs and
humans (reviewed by Huygen [32]). This may be an indication of
species-specific differences in Ag85A epitopes.
There is evidence to suggest that strong T helper 1 (Th1) Ag-
specific CD4+ T cell responses do not necessarily provide the best
protection during pulmonary TB infection but may instead facili-
tate mycobacterial dissemination [34–39]. Indeed, Coscolla et al.
found the majority of TB antigenic proteins are highly conserved
(76% epitopes analysed were in conserved non-essential genes
[34]) and hypothesise there may be a net evolutionary benefit from
T cell recognition for transmission [34,36]. Thus, a more modulated
immune response may be more effective at combating M. bovis
infection as suggested previously by Woodworth et al. [36,38].
Therefore, it may be beneficial to select for CD4+ T cells with a
low avidity for M. bovis Ag in future vaccine strategies.
In summary, although the number of animals used in this study
is relatively small, the results from these experiments indicate that
protection induced by boosting BCG with Ad5-85A is associated
with increased frequencies of Ag85A-specific CD4+ T cells but not
with increased avidity. This study also indicates that Ag-specific
CD4+ T cell epitope spread does not necessarily correlate withPlease cite this article in press as: Metcalfe HJ et al. Protection associated with a
but no increase in avidity for Ag85A. Vaccine (2016), http://dx.doi.org/10.1016the level of protection conferred by the vaccination strategy. To
our knowledge, this is the first study in cattle aiming to determine
whether there is an association between vaccine-induced protec-
tion and Ag-specific CD4+ T cell avidity and repertoire.Funding
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